Abstract Sporotrichosis occurs worldwide, and the metropolitan region of Rio de Janeiro, Brazil, is a main endemic area, with a large number of human and animal cases in the last 19 years. This mycosis is more frequently described in cats rather than in dogs. There are a limited number of oral antifungal agents for the treatment of sporotrichosis in animals. In this context, the effectiveness of terbinafine in the treatment of sporotrichosis in humans, as well as the promising results of in vitro susceptibility tests, inspired us to use this drug in the therapy of this mycosis in dogs. We reported for the first time the use of terbinafine in the treatment of two dogs with sporotrichosis caused by Sporothrix brasiliensis. Moreover, we provided an overview of therapeutic features of canine sporotrichosis cases reported since the 1960s. One of the dogs presented the fixed cutaneous form of the disease, while the other patient presented hyperemia of the nasal mucosa and respiratory signs only. Terbinafine showed high antifungal activity in vitro against the canine Sporothrix isolates. The dogs were successfully treated with terbinafine, with remission of all clinical signs initially presented. The current reports indicate that this drug can emerge as a therapeutic option for canine sporotrichosis.
Introduction
Sporotrichosis is a subcutaneous mycosis caused by thermodimorfic pathogenic species of the genus Sporothrix [1] . This disease occurs worldwide, and the metropolitan region of Rio de Janeiro, located in the southeast region of Brazil, is a main endemic area, with a large number of human and animal cases in the last 19 years [2, 3] . In this country, the most prevalent etiological agent of sporotrichosis is Sporothrix brasiliensis [4] .
Canine sporotrichosis cases are minimal compared to the number of feline cases. Most documented cases in dogs have been from France, USA, Canada, Italy, and especially in Brazil, where the highest number has been reported thus far [3, [5] [6] [7] [8] [9] .
In dogs, the infection can be acquired during hunting activities with the possible introduction of Sporothrix sp. through thorns or wood splinters [10] . However, in Rio de Janeiro, approximately 80% of the cases was because of the dogs being in contact with infected cats [6] . To date, there have been no reports of zoonotic transmission of Sporothrix sp. from infected dogs in Rio de Janeiro [3] .
The cutaneous form of sporotrichosis, with ulcers and/or nodules on the head, ears, neck, back, and thorax, is the most frequently reported in dogs [11] . However, in some cases, cutaneous lesions might not be present [8] . Extracutaneous signs, particularly respiratory signs (sneezing, dyspnea, and nasal discharge), are frequent, and oftentimes related to nasal mucosa lesions [12] . The occurrence of masses protruding from the nostrils can be observed. In addition, most of the cases had presented lymphadenitis, while lymphangitis was uncommon [6, 9] . Rare forms of sporotrichosis that can develop in dogs include osteoarticular and disseminated forms [9, 13, 14] .
Oral itraconazole, ketoconazole, and potassium iodide are the most common drugs used for the treatment of canine sporotrichosis [11] . Terbinafine is an allylamine antifungal agent, which inhibits squalene epoxidase resulting in ergosterol deficiency of the cell wall and intracellular squalene accumulation leading to the death of the fungal cell [15] . This drug is recommended for dermatophytosis [16] and chromoblastomycosis treatment in humans [17, 18] . Reports in dogs involving terbinafine were focused solely on the treatment of malasseziasis and dermatophytosis [19, 20] .
So far the therapeutic potential of terbinafine for sporotrichosis has been confirmed in human patients [21, 22] , and it is especially important when the use of itraconazole is not indicated due to the interaction with other drugs in patients with underlying diseases [21] . At this time, the effectiveness of terbinafine in the treatment of animal sporotrichosis is not known. In contrast, in vitro activity has proven to be effective against Sporothrix sp. isolates from humans, dogs, and cats [23] [24] [25] . Because of this, terbinafine should be considered a potential alternative for the treatment of animal sporotrichosis. Therefore, we report for the first time the use of terbinafine in the treatment of two dogs with sporotrichosis.
Case Reports
Two mongrel dogs, from the metropolitan area of Rio de Janeiro, RJ, Brazil, were presented to the Laboratory of Clinical Research on Dermatozoonosis in Domestic Animals (Lapclin-Dermzoo), Evandro Chagas National Institute of Infectious Diseases (INI)/ Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro. These dogs were castrated, in good overall condition, and with suspicion of sporotrichosis.
The animals underwent a clinical examination and blood collection for hematological and biochemical analyses (urea, creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, and globulin). In addition, biological samples from the dogs were collected for fungal culture. Blood collection and consecutive analyses were performed during and after the antifungal treatment.
Case 1
The 1-year-old dog was a female, weighing 10 kg. The animal was referred to us by a veterinary dermatologist due to the presence of a persistent skin lesion for 12 weeks. The dog did not have contact with any cats. And another dog in the same household did not present any lesion.
During the clinical examination, an ulcerated skin lesion was found on the right lower abdomen area (Fig. 1) . The exudate from the lesion was collected by sterile swab and submitted for a routine mycological examination [6] . No relevant alterations were identified in routine hematology or serum biochemistry panels.
Sporotrichosis was confirmed by the isolation of Sporothrix sp. from the exudate of the skin lesion. This isolate was identified by means of genotypic testing. The genomic DNA was extracted from the mycelial phase, and the isolate was identified using T3B PCR fingerprinting to distinguish between the species of the genus Sporothrix [26, 27] . Strains of the genus Sporothrix associated with clinical cases in humans and animals: S. brasiliensis (IPEC16490), S. globosa (IPEC27135), S. mexicana (MUM11.02), and S. schenckii (IPEC27722) were used as controls for molecular identification. T3B PCR fingerprinting identified the isolate (IPEC14245Z) as S. brasiliensis.
The antifungal susceptibility tests were conducted according to the M38-A2 protocol of the Clinical and Laboratory Standards Institute (CSLI) [28] . Amphotericin B (AMB), terbinafine (TRB), posaconazole (POS), ketoconazole (KTZ), and itraconazole (ITZ) (Sigma Chemical Corporation, St. Louis, MO, USA) were tested. The in vitro antifungal activity tests showed minimum inhibitory concentration (MIC) values for AMB (4.0 lg/mL), TRB (0.06 lg/mL), POS (1.0 lg/mL), KTZ (0.25 lg/mL), and ITZ (0.5 lg/mL).
Oral terbinafine tablets (25 mg/kg) were prescribed once a day with food. The dog was followed up monthly for clinical evaluation and assessment of hematological and biochemical parameters. The clinical cure was achieved at 12 weeks of antifungal therapy, as the animal had no active lesion, merely a scar on the abdomen area (Fig. 1) . The drug was well tolerated, and no clinical or laboratory adverse effects were observed.
The patient returned for an evaluation 23 weeks after discharge. The dog presented in a good overall condition and had no clinical signs of sporotrichosis. No relevant alterations were identified in full blood examination and serum biochemical analysis.
Case 2
The 2-year-old animal was a male, weighing 8.2 kg had a history of respiratory signs in the last year and lived in the same household with cats and his owner, who was previously diagnosed with sporotrichosis.
Inspiratory dyspnea, sneezing, nasal discharge, increased mandibular lymph nodes, and hyperemia in both nostrils were observed during the clinical examination. Skin lesions were not present. No changes were observed in the hematological and serum biochemical analyses.
Nasal secretion was collected by sterile swab for mycological examination. As in Case 1, the diagnosis of sporotrichosis was confirmed by the isolation of Sporothrix sp. in culture, and the result of T3B PCR fingerprinting identified this isolate (IPEC10949) also as S. brasiliensis. The in vitro antifungal activity tests showed MIC values for AMB (4.0 lg/mL), TRB (0.06 lg/mL), POS (1.0 lg/mL), KTZ (0.5 lg/mL), and ITZ (0.5 lg/mL).
Terbinafine tablets (30 mg/kg) were prescribed once a day with food. Clinical follow-up was carried out monthly, as well as the evaluation of laboratorial parameters including complete blood count and serum biochemical analysis.
The respiratory signs ceased after 4 weeks of antifungal treatment. Posteriorly, at the 11th week of treatment, the hyperemia in the nostrils was no longer observed. Mandibular lymphadenomegaly regressed at 15 weeks. After the disappearance of all the clinical signs initially presented, the treatment was maintained for another 4 weeks (totaling 19 weeks), and the animal was discharged. Terbinafine was well tolerated, and no adverse effects were detected during the treatment, moreover no relevant alterations were identified in routine hematology or serum biochemistry panels.
Three months after discharge, the dog returned for an evaluation, and no clinical signs of sporotrichosis were detected. Collection of nasal secretion and blood was performed, and there was no fungal growth, as 
Discussion
Sporotrichosis is a sporadic disease in dogs, and the current knowledge about this mycosis, including therapeutic response, has been obtained from the review of a few isolated cases and the data from the Rio de Janeiro epizootic (Table 1) . Both dogs lived in areas with the heavy transmission of Sporothrix sp. In Case 1, it was not possible to determine the source of the infection, whereas in Case 2, the dog came into contact with infected cats of the same domicile. The identification of canine Sporothrix strains at the molecular level is not common. Sporothrix brasiliensis was the etiological agent of the cases herein presented, and this was the first description of this species in dogs from Rio de Janeiro. The agent was also identified in a few cases from São Paulo and Rio Grande do Sul states, Brazil [1] .
Nowadays, there are a limited number of oral antifungal agents for the treatment of sporotrichosis in animals. In this context, the promising results of in vitro susceptibility tests, as well as the effectiveness of terbinafine in the treatment of sporotrichosis in humans, inspired us to use this drug in the therapy of this mycosis in dogs. To the best of our knowledge, the use of terbinafine to treat a dog with sporotrichosis has not been described previously.
Significant differences in antifungal susceptibilities have been observed among the four pathogenic species of the genus Sporothrix. In general, antifungal drugs show a good response against Sporothrix isolates from Brazil, especially terbinafine [23, [47] [48] [49] [50] . In our reports, terbinafine was effective in vitro and in vivo, with remission of all clinical signs initially presented, as previously described in most cases of sporotrichosis in humans treated with this drug [21, 22, [51] [52] [53] [54] .
The presence of hyperemia in the nasal mucosa and respiratory signs in the absence of skin lesions were observed in Case 2. Despite the occurrence of skin lesions being commonly described in canine sporotrichosis [6] , dogs with nasal involvement with no cutaneous disease are described at a lower rate [8] .
Treatment of canine sporotrichosis has historically involved oral administration of potassium or sodium iodide. In another case report, a dog with cutaneous involvement was treated with saturated solution of potassium iodide [33] . Although the treatment time until the clinical cure was shorter than the dog reported in Case 1, the animal presented adverse effects like weight loss, anorexia, and diarrhea.
The use of ketoconazole and itraconazole to treat dogs with sporotrichosis has been reported, and the duration of the treatment ranged from 8 to 60 weeks and 8 to 20 weeks, respectively [6, 42, 45] . The length of treatment until discharge in the cases reported here was similar to itraconazole treatment time range described above. The presence of hyperemia and respiratory signs in Case 2 might have contributed to the longer time period of treatment in relation to the dog that presented only the skin lesion (Case 1), since the nasal mucosa involvement is typically linked to hard-to-treat lesions [55] and to life-threatening sporotrichosis in cats [56] . Although this correlation is not confirmed in the canine disease, the treatment with terbinafine was successful in Case 2, leading to an optimistic outlook for further studies with this drug.
To the authors' knowledge, in the other only case of intranasal canine sporotrichosis, the animal presented sneezing, nasal congestion, and loss of smell. The dog was treated with oral itraconazole. Pulse therapy with the same drug was chosen following the initial therapy due to the clinical adverse effects related to the azole [8] . In Case 2, treatment time to clinical cure was shorter, and no clinical, nor laboratory adverse effects were observed.
The occurrence of gastrointestinal adverse effects (GAE) such as anorexia, vomiting, or diarrhea, as well as the increase of hepatic enzymes, was described in canine sporotrichosis cases treated with azolic antifungal agents [6] . In dogs with dermatophytosis and malasseziasis treated with terbinafine (20-30 mg/ kg/day), the occurrence of GAE was low [57, 58] , and the increase of alanine aminotransferase was transient, with parameters back to normal 1 week after discharge [58] .
In the cases described here, terbinafine was well tolerated with no clinical adverse effects and no relevant hematological and biochemical changes associated with the treatment. At the moment of reevaluation, the dogs' overall condition was good and had no clinical signs consistent with the disease.
Despite these encouraging outcomes, we are aware that terbinafine's excellent in vitro susceptibility tests results may not necessarily agree with its clinical effectiveness, and evasion from host immunity seems to be the clue for fungal resistance in vivo [59] . This should be especially addressed when it comes to S. brasiliensis, the main species identified in the Rio de Janeiro epidemic and described as being highly virulent. In fact, virulent factors such as melanin production may compromise terbinafine's interaction with the fungal wall, leading to an impairment in its antifungal ability [60] . Having said that, we strongly suggest that some light be shed on these key factors, and that they should be carefully interpreted while evaluating new regimens of treatment for sporotrichosis.
Although terbinafine safety and effectiveness in vivo still need to be further investigated and studies 
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